Back to Search Start Over

Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical Trial.

Authors :
Kapural L
Patterson DG
Li S
Hatheway J
Hunter C
Rosen S
Fishman M
Gupta M
Sayed D
Christopher A
Burgher A
McJunkin T
Ross EL
Provenzano D
Amirdelfan K
Source :
Neuromodulation : journal of the International Neuromodulation Society [Neuromodulation] 2023 Oct; Vol. 26 (7), pp. 1400-1411. Date of Electronic Publication: 2023 Aug 16.
Publication Year :
2023

Abstract

Objective: This study aimed to assess the safety and effectiveness of a new charge-distributed multiphase stimulation paradigm during an extended spinal cord stimulation (SCS) trial.<br />Materials and Methods: This prospective, multicenter, randomized, single-blind, feasibility study included participants with chronic low back and/or leg pain and baseline numerical rating scale (NRS) for overall pain intensity ≥6. After a successful commercial SCS trial, participants were randomized to multiphase SCS therapy A (approximately 600-1500 Hz) or B (approximately 300-600 Hz), delivered via an investigational external pulse generator and existing leads during an 11-to-12-day testing period. Primary end points were mean NRS change from baseline to final in-office visit for each multiphase therapy and between therapies. Secondary end points included mean NRS change from end of commercial trial to final study visit and incidence of device-related adverse events (AEs). Additional measures included patient-reported outcomes collected at home through electronic watches and written diaries. Power usage was compared between multiphase and commercial therapies.<br />Results: A total of 122 participants initiated a commercial trial; 77 were randomized to a multiphase arm, and 65 completed the study. Reductions in mean NRS scores from baseline to final study visit were significant for multiphase therapy A and B (-4.3 and -4.7, respectively; both p < 0.0001). There was no statistically significant difference in mean NRS reduction or percent pain relief between multiphase therapies. In an additional analysis, 63.9% of participants reported greater pain relief with multiphase than with commercial SCS therapy in the at-home setting. On average, multiphase required less power than did commercial devices. One non-serious device-related AE was reported, and no infections occurred during the extended trial.<br />Conclusions: Multiphase SCS effectively reduced pain in participants with chronic low back and/or leg pain during a trial, with no unanticipated device-related AEs reported. Future studies should evaluate long-term effectiveness of multiphase stimulation.<br />Clinical Trial Registration: The Clinicaltrials.gov registration number for the study is NCT03594266.<br /> (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1525-1403
Volume :
26
Issue :
7
Database :
MEDLINE
Journal :
Neuromodulation : journal of the International Neuromodulation Society
Publication Type :
Academic Journal
Accession number :
37589641
Full Text :
https://doi.org/10.1016/j.neurom.2023.05.006